E83.52: Hypercalcemia
E83.52, hypercalcemia, is listed as a covered diagnosis in 4 Medicare billing and coding articles that apply to 68 HCPCS Level II codes, including J1740 (Injection, ibandronate sodium, 1 mg), J3489 (Injection, zoledronic acid, 1 mg), J2430 (Injection, pamidronate disodium, per 30 mg). 25 of these codes have a 2026 DMEPOS fee schedule amount; E0783 pays $9,917.33 to $11,667.45 (NU) depending on the state. The articles come from 3 Medicare contractors. A listed diagnosis supports medical necessity only; coverage still depends on the LCD's criteria and on documentation in the medical record.
HCPCS Level II codes with E83.52 as a covered diagnosis
| Code | Description | Medicare coverage | DMEPOS fee 2026 (state range) | Articles listing it |
|---|---|---|---|---|
| J1740 | Injection, ibandronate sodium, 1 mg | Carrier judgment | — | 2 |
| J3489 | Injection, zoledronic acid, 1 mg | Carrier judgment | — | 1 |
| J2430 | Injection, pamidronate disodium, per 30 mg | Special coverage instructions apply | — | 1 |
| J0897 | Injection, denosumab, 1 mg | Carrier judgment | — | 1 |
| Q5136 | Injection, denosumab-bbdz (jubbonti/wyost), biosimilar, 1 mg | Carrier judgment | — | 1 |
| Q5157 | Injection, denosumab-bmwo (stoboclo/osenvelt), biosimilar, 1 mg | Carrier judgment | — | 1 |
| Q5158 | Injection, denosumab-bnht (bomyntra/conexxence), biosimilar, 1 mg | Carrier judgment | — | 1 |
| Q5159 | Injection, denosumab-dssb (ospomyv/xbryk), biosimilar, 1 mg | Carrier judgment | — | 1 |
| Q5162 | Injection, denosumab-nxxp (bildyos/bilprevda), biosimilar, 1 mg | Carrier judgment | — | 1 |
| Q5165 | Injection, denosumab-mobz (oziltus), biosimilar, 1 mg | Carrier judgment | — | 1 |
| Q5166 | Injection, denosumab-desu (osvyrti/jubereq), biosimilar, 1 mg | Carrier judgment | — | 1 |
| Q5167 | Injection, denosumab-qbde (enoby/xtrenbo), biosimilar, 1 mg | Carrier judgment | — | 1 |
| Q5171 | Injection, denosumab-mobz (boncresa), biosimilar, 1 mg | Carrier judgment | — | 1 |
| E0783 | Infusion pump system, implantable, programmable (includes all components, e.g., pump, catheter, connectors, etc.) | Special coverage instructions apply | $9,917.33–$11,667.45 (NU) | 1 |
| E0786 | Implantable programmable infusion pump, replacement (excludes implantable intraspinal catheter) | Special coverage instructions apply | $10,969.75–$11,380.88 (NU) | 1 |
| E0782 | Infusion pump, implantable, non-programmable (includes all components, e.g., pump, catheter, connectors, etc.) | Special coverage instructions apply | $5,200.92–$6,118.73 (NU) | 1 |
| E0785 | Implantable intraspinal (epidural/intrathecal) catheter used with implantable infusion pump, replacement | Special coverage instructions apply | $572.38–$673.39 (KF) | 1 |
| E0784 | External ambulatory infusion pump, insulin | Special coverage instructions apply | $557.75–$635.90 (RR) | 1 |
| K0455 | Infusion pump used for uninterrupted parenteral administration of medication, (e.g., epoprostenol or treprostinol) | Special coverage instructions apply | $320.84–$483.38 (RR) | 1 |
| E0791 | Parenteral infusion pump, stationary, single or multi-channel | Special coverage instructions apply | $282.07–$427.07 (RR) | 1 |
| E0781 | Ambulatory infusion pump, single or multiple channels, electric or battery operated, with administrative equipment, worn by patient | Special coverage instructions apply | $309.33–$396.36 (RR) | 1 |
| E2103 | Non-adjunctive, non-implanted continuous glucose monitor or receiver | Carrier judgment | $256.09–$334.44 (NU) | 1 |
| A4239 | Supply allowance for non-adjunctive, non-implanted continuous glucose monitor (CGM), includes all supplies and accessories, 1 month supply = 1 unit of service | Carrier judgment | $273.28 | 1 |
| A4238 | Supply allowance for adjunctive, non-implanted continuous glucose monitor (CGM), includes all supplies and accessories, 1 month supply = 1 unit of service | Carrier judgment | $280.71 (KF) | 1 |
| E2102 | Adjunctive, non-implanted continuous glucose monitor or receiver | Carrier judgment | $189.08–$239.22 (NU) | 1 |
43 more codes are listed. See every code with payment by region in Caduvo.
Medicare policy articles listing E83.52
- A56907: Billing and Coding: Bisphosphonate Drug Therapy (WPS Insurance Corporation (MAC - Part A, MAC - Part B); 3 Level II codes). LCD with the same title: L34648
- A52421: Billing and Coding: Ibandronate Sodium (Wellpoint Federal (MAC - Part A, MAC - Part B); 1 Level II codes)
- A52399: Billing and Coding: Denosumab (Prolia®, Xgeva®, Jubbonti®) and biosimilars (Wellpoint Federal (MAC - Part A, MAC - Part B); 10 Level II codes)
- A52507: External Infusion Pumps - Policy Article (CGS Administrators, LLC (DME MAC) Noridian Healthcare Solutions, LLC (DME MAC); 55 Level II codes). LCD with the same title: L33794
A diagnosis listed as covered in a billing and coding article supports medical necessity for the article's codes; it does not guarantee payment. Coverage depends on the LCD's criteria, the contractor's jurisdiction and documentation in the medical record.
Other E83 diagnoses (Disorders of mineral metabolism)
- E83.110 — Hereditary hemochromatosis
- E83.111 — Hemochromatosis due to repeated red blood cell transfusions
- E83.118 — Other hemochromatosis
- E83.19 — Other disorders of iron metabolism
Frequently asked questions
Does Medicare cover E83.52 (Hypercalcemia)?
Medicare covers items and services, not diagnoses. 4 Medicare billing and coding articles list E83.52 as a covered diagnosis for 68 HCPCS Level II codes: the diagnosis can support medical necessity for those codes, but payment still depends on the LCD's coverage criteria and the medical record.
Which HCPCS codes can be billed with ICD-10 E83.52?
The Level II codes from the policies most specific to this diagnosis are J1740 (Injection, ibandronate sodium, 1 mg, 2 articles); J3489 (Injection, zoledronic acid, 1 mg, 1 article); J2430 (Injection, pamidronate disodium, per 30 mg, 1 article); J0897 (Injection, denosumab, 1 mg, 1 article); Q5136 (Injection, denosumab-bbdz (jubbonti/wyost), biosimilar, 1 mg, 1 article). Code choice depends on the item supplied; check each code's descriptor.
What does Medicare pay for equipment billed with E83.52?
Under the 2026 DMEPOS fee schedule (non-rural state fees): E0783 $9,917.33 to $11,667.45 (NU); E0786 $10,969.75 to $11,380.88 (NU); E0782 $5,200.92 to $6,118.73 (NU); E0785 $572.38 to $673.39 (KF). Medicare pays 80% of the allowed amount after the Part B deductible.
Which Medicare policy articles list E83.52?
A56907 (Billing and Coding: Bisphosphonate Drug Therapy); A52421 (Billing and Coding: Ibandronate Sodium); A52399 (Billing and Coding: Denosumab (Prolia®, Xgeva®, Jubbonti®) and biosimilars), and 1 more article.
What is ICD-10-CM code E83.52?
E83.52 is the ICD-10-CM code for hypercalcemia, in category E83 (Disorders of mineral metabolism), chapter 4: Endocrine, nutritional and metabolic diseases.
Next steps
- Run a reimbursement report for a device billed under J1740
- Watch J1740 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J1740
Sources: CMS Medicare Coverage Database billing and coding articles (covered ICD-10 code lists and HCPCS links); ICD-10-CM FY2026; CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule 2026 (non-rural state fees). Not billing or legal advice.
Chapter 4: Endocrine, nutritional and metabolic diseases · All diagnoses · HCPCS lookup